A pretherapy biodistribution and dosimetry study of indium-111-radiolabeled trastuzumab in patients with human epidermal growth factor receptor 2-overexpressing breast cancer

Cancer Biotherapy and Radiopharmaceuticals

Volumn 25, Issue 4, 2010, Pages 387-394

  Wong, Jeffrey Y C ^a   Raubitschek, Andrew ^a   Yamauchi, Dave ^a   Williams, Lawrence E ^a   Wu, Anna M ^b   Yazaki, Paul ^a   Shively, John E ^a   Colcher, David ^a   Somlo, George ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

breast cancer; indium 111; radioimmunotherapy; radiolabeled antibody; trastuzumab

Indexed keywords

CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; METHYL BENZYL ISOTHIOCYANATE PENTETIC ACID TRASTUZUMAB IN 111; PACLITAXEL; RADIOPHARMACEUTICAL AGENT; TRASTUZUMAB; UNCLASSIFIED DRUG; YTTRIUM 90;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; BONE MARROW; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSIMETRY; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; DRUG TOLERABILITY; GENE OVEREXPRESSION; HEART; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; ISOTOPE LABELING; LIVER; ORGAN DISTRIBUTION; PILOT STUDY; PREDICTION; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; URINALYSIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INDIUM RADIOISOTOPES; MIDDLE AGED; PROGNOSIS; RADIOMETRY; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; TISSUE DISTRIBUTION; YTTRIUM RADIOISOTOPES;

EID: 77956138084     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2010.0783     Document Type: Article

References (41)

1. American Cancer Society. Cancer Facts and Figures, Atlanta, GA, 2009.
2. Slamon DJ, Clark J, Wong YC, et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177.
3. Slamon DJ, Goeckeler W, Jones M, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707.
4. Hynes NE. Amplification and overexpression of the erb-2 gene in human tumors: Its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Semin Cancer Biol 1993;4:19.
5. Hynes NE, Stern DF. The biology of erB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994;1198:165.
6. Drebin JA, Link VC, Stern DF, et al. Down modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 1985;41:695.
7. Drebin JA, Link VC, Greene MI. Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. Oncogene 1988;2:273.
8. Drebin JA, Link VC, Greene MI. Monoclonal antibodies specific for the neu oncogene product directly mediate antitumor effects in vivo. Oncogene 1988;2:387.
9. Fendly BM, Winget M, Hudziak RM, et al. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 1990;50:1550.
10. Aboud-Pirak E, Hurwitz E, Pirak ME, et al. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst 1988;80:1605.
11. Pietras RJ, Fendly BM, Chazin VR, et al. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994; 9:1829.
12. Hancock MC, Langton BC, Chan T, et al. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 1991;51:4575.
13. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783.
14. Cobleigh , Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639.
15. Crow DM, Williams L, Colcher D, et al. Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol. Bioconjug Chem 2005;16:1117.
16. Kotts CE, Hutchins BM, Leddy CA, et al. Internalization of humanized monoclonal antibody against p185-HER2. Proc Annu Meet Am Assoc Cancer Res 1993;34:A2839.
17. Chen KT, Lee TW, Lo JM. In vivo examination of 188Re(Itricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer. Nucl Med Biol 2009;36:355.
18. Akabani G, Carlin S, Welsh P, et al. In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: Effect of specific activity and HER2 receptor heterogeneity on survival fraction. Nucl Med Biol 2006;33:333.
19. Luo T-Y, Tang I-C, Wu Y-L, et al. Evaluating the potential of 188 Re-SOCTA-trastuzumab as a new radioimmunoagent for breast cancer treatment. Nucl Med Biol 2009;36:81.
20. Rasaneh S, Rajabi H, Babaei MH, et al. Radiolabeling of trastuzumab with 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer. Nucl Med Biol 2009;36:363.
21. Milenic DE, Garmestani K, Brady ED, et al. Potentiation of high-LET radiation by gemcitabine: Targeting HER2 with trastuzumab to treat disseminated peritoneal disease. Clin Cancer Res 2007;13:1926.
22. Perik PJ, Lub-De-Hooge MN, Gietema JA, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2006;24:2276.
23. Borchardt PE, Yuan RR, Miederer M, et al. Targeted Actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res 2003;63:5084.
24. Costantini DL, Chan A, Cai Z, et al. 111In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): An auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med 2007;48:1357.
25. De Santes K, Slamon D, Anderson SK, et al. Radiolabeled antibody targeting of the HER-2/neu oncoprotein. Cancer Res 1992;52:1916.
26. Tsai SW, Sun LE, Williams LE, et al. Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5. Bioconjug Chem 2000;11:327.
27. Milenic DE, Garmestani K, Brady ED, et al. Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. Clin Cancer Res 2004;10:7834.
28. Wong JYC, Thomas GE, Yamauchi DM, et al. Clinical evaluation of Indium-111-labeled chimeric anti-CEA monoclonal antibody. J Nucl Med 1997;38:1951.
29. Odom-Maryon TL, Williams LE, Chai A, et al. Pharmacokinetic modeling and absorbed dose estimation for a chimeric anti-CEA antibody (cT84.66) in humans. J Nucl Med 1997;38:1959.
30. Loevinger R, Berman M. MIRD Pamphlet No.1. A schema for absorbed-dose calculations for biologically-distributed radionuclides. J Nucl Med 1968;9 (supplement 1):7.
31. Stabin MG. MIRDOSE: Personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996;37:538.
32. Siegel JA, Wessels BW, Watson EE, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconj Radiopharm 1990;3:213.
33. Thomas SR, Maxon HR, Kereiakes JG. In vivo quantitation of lesion radioactivity using external counting methods. Med Phys 1976;3:253.
34. Loevinger R, Japha EM, Brownell GL. Discrete radioisotope sources. In: Hine GJ, Brownell GL (eds.). Radiation Dosimetry. New York: Academic Press, Inc., 1956:732.
35. Loevinger R, Holt JG, Hine GJ. Internally administered radioisotopes. In: Hine GJ, Brownell GL (eds.). Radiation Dosimetry. New York: Academic Press, Inc., 1956:824.
36. Wong JY, Chu DZ, Yamauchi D, et al. Dose escalation imaging trial evaluating indium-111-labeled anti-CEA chimeric monoclonal antibody (cT84.66) in presurgical colorectal cancer patients. J Nucl Med 1998;39:2097.
37. Wong JYC, Chu DZ, Yamauchi DM, et al. Phase I radioimmunotherapy trials evaluating Y-90 labeled anti-CEA chimeric T84.66 in patients with metastatic CEA-producing malignancies. Clin Cancer Res 2000;6:3855.
38. Wong JYC, Somlo G, Odom-Maryon T, et al. Initial results of a phase I trial evaluating yttrium-90 (90Y) Chimeric T84.66 (cT.84.66) anti-CEA antibody and autologous stem cell support in CEA-producing metastatic breast cancer. Clin Cancer Res 1999;5:3224s.
39. Behr TM, Behe M, Angerstein C, et al. Does pretherapeutic immunoscintigraphy allow for diagnostic predictions with respect to the toxicity and therapeutic efficacy of cold immunotherapy with trastuzumab (Herceptin)? J Nucl Med 2000;41:73P.
40. Wong JYC. Systemic targeted radionuclide therapy: Potential new areas. Int J Radiat Oncol Biol Phys 2006; 66:S74.
41. Meredith R, Wong JYC, Knox SJ. Targeted radionuclide therapy. In: Gunderson LG, Tepper JE (eds.). Clinical Radiation Oncology, 2nd ed. Pennsylvania: Churchill Livingstone, 2006:407.